Get started
Work

A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit–positive Acute Myeloid Leukemia

Year: 2020
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.clml.2020.11.018
Authors: Anjali S. Advani, William Tse, Hong Li, Xuefei Jia, Paul Elson, Brenda Cooper, Francis Ali-Osman, Jino Park, Arati V. Rao, David A. Rizzieri, Eunice S. Wang, Claudiu V. Cotta, Matt Kalaycio, Ronald M. Sobecks, Basel Rouphail, Jaroslaw P. Maciejewski, Jaime Fensterl, Jennifer S. Carew, Bethany Foster, Mary Lynn Rush, Barbara Tripp, Donna Adams, Donna Corrigan, Elizabeth A. Griffiths, Mikkael A. Sekeres
Institutions: Cleveland Clinic, MetroHealth, University Hospitals of Cleveland, University Hospitals Cleveland Medical Center, Duke University, University of Louisville, Duke Cancer Institute, Roswell Park Comprehensive Cancer Center, University of Arizona Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
Funders: Pfizer, Astellas Pharma US, Novartis, Gilead Sciences, AbbVie, Novartis Pharmaceuticals Corporation, Daiichi-Sankyo, Genentech
OpenAlex ID: W3107027296
FWCI: 0.54
Cites: 10
Cited by: 5
Related to: 10